Biomarker-informed care for patients with renal cell carcinoma
- PMID: 40240621
- DOI: 10.1038/s43018-025-00942-1
Biomarker-informed care for patients with renal cell carcinoma
Abstract
Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for patients with ccRCC, either as adjuvant therapy or combined with other agents in advanced disease. However, biomarkers to predict therapeutic benefits are lacking. Here, we explore biomarkers that predict therapeutic response in other tumor types and discuss the reasons for their ineffectiveness in ccRCC. We also review emerging predictive and prognostic biomarkers to prioritize in ccRCC, including gene expression signatures.
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Competing interests: M.B.M. has nothing to disclose. B.I.R. is a consultant for and receives research funding from Merck, Eisai, Genentech, BMS and Pfizer. S.M.H. is a consultant for Exelixis and Tempus.
References
-
- Atkins, M. B. Clinical presentation, diagnosis, and staging of renal cell carcinoma. In UpToDate (ed. Richie, J. P.) (Wolters Kluwer, 2023).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
